Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

多发性骨髓瘤 医学 泊马度胺 来那度胺 耐火材料(行星科学) 内科学 Carfilzomib公司 肿瘤科 重症监护医学 生物 天体生物学
作者
Surbhi Sidana,Krina K. Patel,Lauren C. Peres,Radhika Bansal,Mehmet H. Kocoglu,Leyla Shune,Shebli Atrash,Kinaya Smith,Shonali Midha,Christopher Ferreri,Binod Dhakal,Danai Dima,Patrick Costello,Charlotte B Wagner,Ran Reshef,Hitomi Hosoya,Lekha Mikkilineni,Djordje Atanackovic,Saurabh Chhabra,Ricardo Parrondo
出处
期刊:Blood [Elsevier BV]
被引量:13
标识
DOI:10.1182/blood.2024025945
摘要

Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 3/1/2022-12/31/2022 at 16 US academic medical centers were included. RESULTS: 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel. Of leukapheresed patients, 56% would not have met CARTITUDE-1 trial eligibility criteria. Manufacturing failure rates at first attempt and overall were 6% and 1%, respectively. Median prior lines of therapy were 6. In treated patients (N=236), cytokine release syndrome was seen in 75% (>= grade 3: 5%), immune effector cell-associated neurotoxicity syndrome in 14% (>= grade 3: 4%), and delayed neurotoxicity in 10%. Best overall and >= CR rates were as follows: infused patients (N=236): 89% and 70%; patients receiving conforming CAR-T product (N=191) 94% and 74%; conforming CAR-T product with fludarabine/cyclophosphamide lymphodepletion (N=152): 95% and 76%, respectively. Non-relapse mortality was 10%, most commonly from infection. After median follow-up of 13 months from CAR-T, median progression-free survival (PFS) was not reached, with 12- month estimate being 68% (95% CI: 62-74%). High ferritin levels, high-risk cytogenetics, and extramedullary disease were independently associated with inferior PFS, with a signal for prior BCMA-TT (p=0.08). Second primary malignancies (SPMs) excluding non-melanoma skin cancers were seen in 5.5% and myeloid malignancies/acute leukemia in 1.7%. We observed a favorable efficacy profile of standard of care cilta-cel in RRMM despite more than half the patients not meeting CARTITUDE-1 eligibility criteria.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
橘子发布了新的文献求助10
刚刚
刚刚
1秒前
1秒前
wjx发布了新的文献求助10
2秒前
2秒前
3秒前
3秒前
iNk应助你怎么睡得着觉采纳,获得20
3秒前
橙子完成签到,获得积分20
3秒前
3秒前
雪白的山雁完成签到,获得积分10
4秒前
ZZ发布了新的文献求助10
4秒前
ks完成签到,获得积分10
5秒前
5秒前
Grace发布了新的文献求助10
6秒前
小小猪发布了新的文献求助10
7秒前
STOOd发布了新的文献求助10
7秒前
Goodluck发布了新的文献求助10
7秒前
Sarah完成签到,获得积分10
8秒前
8秒前
Z可发布了新的文献求助10
8秒前
慕青应助wawaeryu采纳,获得50
9秒前
华仔应助神奇小鹿采纳,获得10
10秒前
fanfan发布了新的文献求助10
11秒前
随意完成签到,获得积分10
11秒前
12123ray完成签到,获得积分20
11秒前
lu发布了新的文献求助10
11秒前
量子星尘发布了新的文献求助10
12秒前
12秒前
小小猪完成签到,获得积分10
14秒前
乐观的乐松完成签到,获得积分10
14秒前
樱悼柳雪发布了新的文献求助50
15秒前
Hhhhhh发布了新的文献求助10
15秒前
归仔发布了新的文献求助10
15秒前
完美世界应助大气的一德采纳,获得10
16秒前
传奇3应助12123ray采纳,获得10
16秒前
UU完成签到,获得积分10
16秒前
Abyss完成签到,获得积分10
17秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974882
求助须知:如何正确求助?哪些是违规求助? 3519431
关于积分的说明 11198315
捐赠科研通 3255698
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877237
科研通“疑难数据库(出版商)”最低求助积分说明 806219